
Immunovant, Inc. – NASDAQ:IMVT
Immunovant stock price today
Immunovant stock price monthly change
Immunovant stock price quarterly change
Immunovant stock price yearly change
Immunovant key metrics
Market Cap | 3.79B |
Enterprise value | 1.45B |
P/E | -8.72 |
EV/Sales | N/A |
EV/EBITDA | -7.50 |
Price/Sales | N/A |
Price/Book | 4.54 |
PEG ratio | 0.50 |
EPS | -1.74 |
Revenue | N/A |
EBITDA | -233.53M |
Income | -223.30M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeImmunovant stock price history
Immunovant stock forecast
Immunovant financial statements
Dec 2021 | 0 | -41.38M | |
---|---|---|---|
Mar 2022 | 0 | -47.17M | |
Mar 2023 | 0 | -59.43M | |
Mar 2024 | 0 | -75.31M |
Sep 2025 | 0 | -94.66M | |
---|---|---|---|
Oct 2025 | 0 | -95.20M | |
Dec 2025 | 0 | -95.93M | |
Mar 2026 | 0 | -98.99M |
Analysts Price target
Financials & Ratios estimates
Sep 2022 | 428146000 | 32.39M | 7.57% |
---|---|---|---|
Dec 2022 | 456243000 | 41.56M | 9.11% |
Mar 2023 | 405838000 | 43.34M | 10.68% |
Mar 2024 | 666712000 | 48.95M | 7.34% |
Dec 2021 | -31.89M | -74K | 0 |
---|---|---|---|
Mar 2022 | -32.95M | -118K | 0 |
Mar 2023 | -55.79M | -26K | 233K |
Mar 2024 | -59.69M | -150K | 1.54M |
Immunovant alternative data
Sep 2023 | 164 |
---|---|
Oct 2023 | 164 |
Nov 2023 | 164 |
Dec 2023 | 164 |
Jan 2024 | 164 |
Feb 2024 | 164 |
Mar 2024 | 164 |
Apr 2024 | 164 |
May 2024 | 164 |
Jun 2024 | 164 |
Jul 2024 | 207 |
Immunovant other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 22188 |
Feb 2024 | 0 | 22885 |
Apr 2024 | 0 | 98566 |
May 2024 | 0 | 29941 |
Jul 2024 | 0 | 41401 |
Aug 2024 | 0 | 28185 |
Oct 2024 | 0 | 38326 |
Nov 2024 | 0 | 27869 |
Dec 2024 | 0 | 13175 |
Quarter | Transcript |
---|---|
Q4 2022 9 Jun 2022 | Q4 2022 Earnings Call Transcript |
Q1 2022 9 Aug 2021 | Q1 2022 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Peter Salzmann M.B.A., M.D. (1968) Chief Executive Officer & Director | $1,020,000 |
Dr. Julia G. Butchko Ph.D. (1971) Chief Devel. & Technology Officer | $531,000 |
Dr. Frank M. Torti M.B.A., M.D., MBA (1979) Executive Chairperson of the Board | $97,500 |
Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study
Argenx: Strong Setup For Outperformance In 2025
Immunovant: Overvalued Amidst M&A Speculation
Roivant Sciences: Executing On Huge Buyback Program With More To Come
Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023
Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena
Roivant Sciences: Risk-Transforming Deal Met With Crickets
-
What's the price of Immunovant stock today?
One share of Immunovant stock can currently be purchased for approximately $14.82.
-
When is Immunovant's next earnings date?
Unfortunately, Immunovant's (IMVT) next earnings date is currently unknown.
-
Does Immunovant pay dividends?
No, Immunovant does not pay dividends.
-
How much money does Immunovant make?
Immunovant has a market capitalization of 3.79B.
-
What is Immunovant's stock symbol?
Immunovant, Inc. is traded on the NASDAQ under the ticker symbol "IMVT".
-
What is Immunovant's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Immunovant?
Shares of Immunovant can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Immunovant's key executives?
Immunovant's management team includes the following people:
- Dr. Peter Salzmann M.B.A., M.D. Chief Executive Officer & Director(age: 57, pay: $1,020,000)
- Dr. Julia G. Butchko Ph.D. Chief Devel. & Technology Officer(age: 54, pay: $531,000)
- Dr. Frank M. Torti M.B.A., M.D., MBA Executive Chairperson of the Board(age: 46, pay: $97,500)
-
How many employees does Immunovant have?
As Jul 2024, Immunovant employs 207 workers, which is 26% more then previous month and 26% more then previous quarter.
-
When Immunovant went public?
Immunovant, Inc. is publicly traded company for more then 6 years since IPO on 21 Jun 2019.
-
What is Immunovant's official website?
The official website for Immunovant is immunovant.com.
-
Where are Immunovant's headquarters?
Immunovant is headquartered at 320 West 37th Street, New York, NY.
-
How can i contact Immunovant?
Immunovant's mailing address is 320 West 37th Street, New York, NY and company can be reached via phone at +91 75803099.
Immunovant company profile:

Immunovant, Inc.
immunovant.comNASDAQ
207
Biotechnology
Healthcare
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
New York, NY 10018
CIK: 0001764013
ISIN: US45258J1025
CUSIP: 45258J102